Staff Members - Benha University
Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure
Advances in Virology • 2020
Publication Information
Authors
Yousry Esam-Eldin Abo-amer,1 Rehab Badawi,2 Mohamed El-Abgeegy,3
Heba Fadl Elsergany,3 Ahmed Abdelhaleem Mohamed,3 Sahar Mohamed Mostafa,3
Hatem Samir Alegaily,4 Shaimaa Soliman,5 Sally Elnawasany,2 and Sherief Abd-Elsalam 2
Keywords
Quadruple, therapy, HCV, genotype 4
Journal
Advances in Virology
Publisher
Hindawi
Volume
Not Available
Issue
Not Available
Pages
6 pages
publication.type
International
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
Background and Aims. Direct-acting antivirals (DAAs) have made a revolution in hepatitis C virus (HCV) treatment with
promising reduction of HCV infection and disease morbidities. However, unfortunately, treatment failure still occurs in about
5–15% of patients treated with DAA-based combination regimens. *e primary aim of the study was to assess the efficacy and
safety of a quadruple regimen of (sofosbuvir, daclatasvir, and simeprevir with a weight-based ribavirin) in chronic HCV DAAsexperienced patients. Methods. *is observational, open-label prospective study was carried out on 103 genotype 4 hepatitis C
virus-infected patients who failed to achieve SVR12 after sofosbuvir-daclatasvir with or without ribavirin. Patients were treated for
three months with sofosbuvir (400 mg), daclatasvir (60 mg), and simeprevir (150 mg) with a weight-based ribavirin dosage
(1000–1200 mg/d). Response to treatment was determined by quantitative PCR for HCV at 3 months after the end of treatment
(SVR12), and adverse events during the treatment were recorded. Results. SVR was achieved in 100 patients (97.1%) at week 12
after treatment. No dangerous or life-threatening adverse events were recorded. Conclusions. Retreatment of HCV genotype 4
patients with quadruple therapy is a good therapeutic option and achieves high response rates with minimal side effects.
promising reduction of HCV infection and disease morbidities. However, unfortunately, treatment failure still occurs in about
5–15% of patients treated with DAA-based combination regimens. *e primary aim of the study was to assess the efficacy and
safety of a quadruple regimen of (sofosbuvir, daclatasvir, and simeprevir with a weight-based ribavirin) in chronic HCV DAAsexperienced patients. Methods. *is observational, open-label prospective study was carried out on 103 genotype 4 hepatitis C
virus-infected patients who failed to achieve SVR12 after sofosbuvir-daclatasvir with or without ribavirin. Patients were treated for
three months with sofosbuvir (400 mg), daclatasvir (60 mg), and simeprevir (150 mg) with a weight-based ribavirin dosage
(1000–1200 mg/d). Response to treatment was determined by quantitative PCR for HCV at 3 months after the end of treatment
(SVR12), and adverse events during the treatment were recorded. Results. SVR was achieved in 100 patients (97.1%) at week 12
after treatment. No dangerous or life-threatening adverse events were recorded. Conclusions. Retreatment of HCV genotype 4
patients with quadruple therapy is a good therapeutic option and achieves high response rates with minimal side effects.